Welcome to the webinar!

Epidemiological Tools and Analytics to Support the Global Elimination of Hepatitis B

January 23, 2019
Hep B United is a national coalition that was established by the Hepatitis B Foundation and the Association of Asian Pacific Community Health Organizations to address the public health challenge of hepatitis B.

The coalition is dedicated to reducing the health disparities associated with hepatitis B by increasing awareness, screening, vaccination, and linkage to care for high-risk communities across the United States.
Devin Razavi-Shearer
HBV/HDV Project Lead
Center for Disease Analysis Foundation
Epidemiological Tools and Analytics to Support the Global Elimination of Hepatitis B

D. Razavi-Shearer

January 23rd, 2019
Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- PRoGReSS Model
  » Overview
  » Model Validation
  » Economic Impact
  » Immigration
- Model
CDA Foundation (CDAF) is a non-profit organization with the goal of assisting countries in achieving the 2030 hepatitis elimination targets.

We work to **study, model & eliminate** hepatitis. We accomplish this through our two major initiatives:

**Study**
- **POLARIS OBSERVATORY**
  - Provide collaborators with epidemiological data, modeling tools and decision analytics to support eliminating Hepatitis B and C globally by 2030.

**Model**

**Eliminate**
- **GPRO FUND**
  - Improve access to medicines and diagnostics, and develop scalable, sustainable funding mechanisms for low and middle-income (LMIC) countries. Provide optimized hepatitis elimination programs.
CDAF provides technical assistance to aid in the decision making process

<table>
<thead>
<tr>
<th>Services</th>
<th>Guiding Principles</th>
</tr>
</thead>
<tbody>
<tr>
<td>- HCV &amp; HBV disease burden modeling</td>
<td>- Validate all data/analyses with local experts</td>
</tr>
<tr>
<td>- HCV &amp; HBV economic impact modeling</td>
<td>- Complement country interviews with literature searches to minimize the burden on country experts</td>
</tr>
<tr>
<td>- HBV vertical and horizontal transmission modeling</td>
<td>- Facilitate objective, data-driven decisions and policy-making with consideration of each country’s unique needs</td>
</tr>
<tr>
<td>- Cohort analysis</td>
<td>- Publish key findings with local collaborators</td>
</tr>
<tr>
<td>- Training on how to use models</td>
<td>- Function as a platform to provide data, tools and analyses with a user-friendly Microsoft Excel® interface</td>
</tr>
<tr>
<td>- Hepatitis elimination strategies</td>
<td></td>
</tr>
<tr>
<td>- Cost-effectiveness and ROI analyses</td>
<td></td>
</tr>
<tr>
<td>- Data and metrics to track progress to elimination</td>
<td></td>
</tr>
</tbody>
</table>
We have modeled hepatitis disease burden for over 100 countries/regions in collaboration with more than 750 country experts.
The Polaris Observatory keeps track of how countries are progressing & provides guidance on how they can achieve the elimination targets.
Topics

• CDAF Background

• Delphi Process

• Global Work

• State Work

• PRoGReSs Model
  » Overview
  » Model Validation
  » Economic Impact
  » Immigration

• Model
A modified Delphi process is used to develop consensus estimates for all inputs.
A systematic process is used to develop consensus estimates of HBV disease burden in each country

- **Pre-Meeting 1**
  - Conduct an exhaustive literature search for English and non-English published studies finding key inputs — HBsAg prevalence, age distribution, HBeAg prevalence among women of childbearing age, diagnosed, treated, incidence
  - Pre-populate the disease burden model and send out a slide deck summarizing findings

- **Meeting 1 with local experts (2 hours)**
  - Provide a brief overview of the methodology and model
  - Review assumptions and identify data gaps
  - Make modifications to key inputs based on expert input and unpublished data
  - Identify action items with key responsibilities

- **Between Meetings 1 & 2**
  - Work with stakeholders to gather additional data and re-calibrate the model

- **Meeting 2 teleconference with local experts (1.5 hours) if necessary**
  - Review updated inputs and gain consensus
  - Review the scenarios and discuss any additional analysis

- **Post-Meeting 2**
  - Develop manuscripts to be submitted to peer-reviewed journals
  - Submit abstracts to conferences to present findings
Publications & Citations

- CDAF partners with our collaborators to publish data, analyses and related findings.
- Since 2011, together we have published **65 papers** in prominent, peer reviewed journals.
- Polaris and its collaborators have over **4,500 citations**, and growing.
Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- PRoGReSs Model
  - Overview
  - Model Validation
  - Economic Impact
  - Immigration
- Model
As part of the Polaris Observatory, the following HBV projects are underway:

• HBV epidemiology
   » HBsAg prevalence
   » HBeAg prevalence
   » HDV prevalence

• PRoGReSs Model
   » HBV perinatal and horizontal transmission model with disease burden
   » Economic Impact Module
   » Immigration Module
A data quality scoring system was developed to select the most representative studies – only studies with a score of $\geq 3$ are used.

<table>
<thead>
<tr>
<th>Geographic Scope</th>
<th>Scale, 0–10</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>0</td>
</tr>
<tr>
<td>Large Region Multi-Region</td>
<td>0</td>
</tr>
<tr>
<td>Multi-City Large City</td>
<td>0</td>
</tr>
</tbody>
</table>

### Population →

**High risk, any sampling method**
- IVDUs
- HIV
- Surgical patients

**Healthy adults, self-selected**
- Blood donors
- Health check-up patients Screening

**Healthy adults, randomly selected**
- Health care workers
- Pregnant women
- Soldiers

**General population, randomly selected**

†10 reserved for a nationally representative sample with a stratified, multistage and random sampling design, which documents the study design and demographics of subjects thoroughly (e.g. NHANES).
‡Variability subject to authors discretion based on quality of study design, as well as the geographic scope of the respective country.
Data was available for 93% of the global population and 90% of all estimated HBsAg+ infections

Global HBsAg prevalence was 3.9% (3.4-4.6%) corresponding to 292 million (252-341) infections in 2016.
A large disparity in access to tools to reduce mother-to-child-transmission exists across countries.
The global HBsAg prevalence among 5-year olds was estimated to be 1.4% (1.2-1.6%) representing 1.8 million (1.6-2.2) infections in 2016.
20 countries will not reduce their HBsAg prevalence to less than 1.0% by 2020 and 0.1% by 2030 among 5-year-olds.

Polaris Observatory (http://cdafound.org/polaris/ accessed June 14, 2018)
Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- PRoGReSs Model
  - Overview
  - Model Validation
  - Economic Impact
  - Immigration
- Model
Past State Work - HCV

• Quantify HCV epidemiology at the state level
  » Prevalence by age, diagnosed, treated, incidence

• Model HCV disease burden at the state level
  » Fibrosis, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver transplants

• Model future HCV disease burden under the current standard of care

• Model the requirement to achieve HCV elimination by 2030
The HCV epidemiology, disease burden and elimination has been assessed in 14 states and the District of Columbia

• Independent analysis of HCV disease burden and elimination targets in the United States\textsuperscript{1,2}

• States modeled in collaboration with local health departments
  
  » Colorado, District of Columbia, Kentucky, Rhode Island\textsuperscript{3}

• States modeled in collaboration with the CDC Foundation and local health departments
  
  » California, Louisiana, New York*, Ohio, Washington

• States modeled in collaboration with ASTHO and local health departments
  
  » Georgia, Iowa, Maryland, New Mexico, Pennsylvania, Tennessee


* Meetings in progress, or being planned, with experts
Future ASTHO Project – Planning for State Viral Hepatitis Elimination Programs

• Unfortunately, the due date for applications was January 22nd

• This project will support approximately 30 states or territorial health departments with the following activities available:
  » Local hepatitis B and C burden estimates (collaboration with CDAF)
    ▪ Gain consensus on prevalence estimates
    ▪ Model the disease burden
    ▪ Work with states to develop elimination targets
  » Hepatitis B and C elimination planning (collaboration with CDAF)
  » Demonstration projects for viral hepatitis elimination plans that have been or are being implemented

• In addition, CDAF is planning a conference to provide elimination strategy guidance, share best practices and lessons learned
  » More details will be available in a month
Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- **PRoGReSs Model**
  - Overview
  - Model Validation
  - Economic Impact
  - Immigration
- Model
CDA models characteristics

- **Easy to use platform** – Excel-based model
- **Transparent** – All formulas are unprotected and visible
- **Ties to historical data** – Published data is used to calibrate the model
- **Measures the impact of future decisions** – Interface to input potential strategies

**Input**
Contains input data for Population, Incidence, Mortality Rates, Disease Progression Rates and several other measures.

**Calculations**
Calculates the progression of patients and associated costs from Incidence (newly infected) to Cured or Death.

**Outputs**
Displays a summary table of the key output measures and more detailed results in numerous charts.

**Dashboard**
User input sheet for assumptions about future Incidence, Diagnosis, Treatment Eligibility, SVR Rates and Costs.
PRoGReSs Model — Inputs, non-perinatal

- Demographic
  - Population by year, sex, and age
  - Background mortality by year, sex, and age group

- Epidemiological
  - Newly diagnosed patients by year
  - Antiviral treatments
    - Total patients (stock) receiving treatment by year
    - Mean duration of treatment
  - Liver transplants
    - Total transplantations by year
    - Proportion of transplantations attributed to HBV
PRoGReSs Model — Inputs, perinatal

• Demographic
  » Male-to-female sex ratios at birth, quinquennial
  » Births by mother’s age group, by year

• Epidemiological
  » HBeAg prevalence among HBsAg+ women of childbearing age
  » Prophylaxies coverage
    ▪ Women of childbearing age: peripartum antiviral treatment
    ▪ Infants
      – Timely birth dose of HBV vaccine
      – Complete HBV vaccine series
      – HBIG, of those receiving timely birth dose
    ▪ Non-infants: complete HBV vaccine series
PRoGReSs Model — Collecting input data

• Prevalence
  » PubMed and Embase were utilized to search:
    ▪ “[Country Name] AND (‘prevalence’/exp OR prevalence) AND (‘hepatitis b’/exp OR ‘hepatitis b’ OR ‘hbv’/exp OR ‘hbv’)”
    ▪ All countries with a population over 1 million as well as Belize, Fiji, and Kiribati
  » 42 691 studies identified with estimates for 128 countries
  » 121 country level models were built

• Prophylaxes Coverage
  » WHO/UNICEF coverage rates were supplemented by:
    ▪ PAHO Report
    ▪ 2013 WHO Global Policy Report on Prevention and Control of Viral Hepatitis
    ▪ National Guidelines
    ▪ Country Interviews
HBV Perinatal Transmission

- Developed a perinatal transmission algorithm to estimate the full impact of vaccination, HBIG, and treatment of pregnant women on HBsAg prevalence
- The model uses:
  - Age-specific HBsAg prevalence among women of childbearing age (WoCBA)
  - Overall HBeAg prevalence among WoCBA
  - Portions of HBeAg+ and HBeAg- populations with high viral load (HVL) and low viral load (LVL)
- Births by age group of mother are utilized
- All infected female infants are tracked to estimate HBV prevalence when they become WoCBA
- After perinatal transmission of HBV, risk for developing a chronic HBV infection is 0.885 (Edmunds 1993)


HBV Horizontal Transmission

- Horizontal transmission covers all transmission occurring non-perinatally
- Horizontal incidence of acute HBV is assumed to be a linear function $I$ of prevalence of HBsAg with high viral load $p$ for a population of susceptible individuals $S$ at time $t$, of sex $s$, and age $a$. For those younger than 15, incidence is based on the prevalence of those aged 1–35 to simulate household infection from siblings, peers, parents, and other adults. For those 15 or older, incidence is based on the prevalence among peers of the same age:

$$ I_{t,s,a} = \begin{cases} S_{t-1,s,a-1} \times (1 - d_{t-1,s,a-1}) \times p_{t-1,0-35} \times (k_a \times C_s) & \text{if } 0 \leq a < 15 \\ S_{t-1,s,a-1} \times (1 - d_{t-1,s,a-1}) \times p_{t-1,a} \times (k_a \times C_s) & \text{if } a \geq 15 \end{cases} $$

where $d$ is background mortality rate, $k$ is the shape parameter, and $C$ is the scale parameter

- Individuals acquiring acute HBV infection are removed from the susceptible population
- After horizontal transmission of HBV, risk $c$ for developing a chronic HBV infection at age $a$ is calculated using:

$$ c_a = \begin{cases} c_1 & \text{if } a = 0 \\ 1 - 0.7145a^{0.0814} & \text{if } 1 \leq a < 35 \\ c_{34} & \text{if } a \geq 35 \end{cases} $$

HBV Disease Progression

- **Immune and recovered**
  - Infant vaccination
  - Catch-up vaccination
  - Clearance

- **Susceptible infants (<1 year old)**
  - Aging
  - Incidence
  - Perinatal and horizontal

- **Susceptible population (≥1 year old)**

- **Acute hepatitis B**
  - Fulminant hepatitis B death

- **Chronic hepatitis B**
  - Progression

- **Compensated cirrhosis**
  - Progression

- **Decompensated cirrhosis**
  - Progression

- **Hepatocellular carcinoma**
  - Progression

- **Liver transplant**
  - Transplantation

- **Liver-related death**
Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- PRoGReSs Model
  - Overview
  - Model Validation
    - Economic Impact
    - Immigration
- Model
Model validation

• Objective of validation: accurately predict age-specific prevalence of HBsAg
• Prevalence studies with at least two time points were chosen
  » China
  » Iran
  » United States
• Chosen countries vary by
  » Region
  » HBsAg prevalence
  » HBeAg prevalence
  » Genotype
• Reported prevalence of HBsAg was compared to modeled prevalence

Model validation — China

- Calibrate model to reported HBsAg prevalence in 1992 (Xia 1996)
  - Compare modeled prevalence in 2014 by birth year to reported 2006 (Liang 2013) and 2014 (Cui 2017) data
    - Base modeled prevalence was a good match to reported data for birth years until 1988; low modeled prevalence was a good match for birth years after 1988

---

Model validation — China

- Calibrate model to reported HBsAg prevalence in 2006
  - Compare modeled prevalence by birth year to reported 1992 and 2014 data
    - Modeled prevalence was a good match to reported data in all years, particularly among those born after 2006

Model validation — Iran

- Calibrate model to reported pre-vaccination HBsAg prevalence in 1990 (Zali 2005)
- Compare modeled HBsAg prevalence to reported 1999 data (Zali 2005)
  » Modeled overall, age- and sex-specific HBsAg prevalence was a good match to reported data

Model validation — United States

- Calibrate model to reported HBsAg prevalence in NHANES 1988–1994 (Roberts 2016)
- Compare modeled number of HBsAg infections in 2003 and 2010 to reported NHANES 1999–2006 (Roberts 2016) and NHANES 2007–2012 (Roberts 2016) data, respectively
  - Model predicts well within the CIs, with less HBsAg infections than those reported in NHANES 2007–2012
    - Model was used to estimate global prevalence of HBsAg, so it did not consider the impact of “new” cases of HBV entering through immigration
    - Model is able to take into account the impact of immigration if data is available
- Compare modeled overall, age- and sex-specific HBsAg prevalence to reported NHANES 2007–2012 data
  - Model predicts HBsAg prevalence within the reported CIs except for age group 6–19, where modeled prevalence is slightly higher
    - It was assumed that HBsAg prevalence collected in 1988–1994 was representative of prevalence in 1991. Because this was in the early years of the era of vaccination, even a few years of difference in the year of calibration can have a considerable impact on modeled outputs

Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- PRoGReSS Model
  - Overview
  - Model Validation
    - Economic Impact
    - Immigration
- Model
PRoGReSs — Economic Impact Module — Overview

**Future strategies**

- **Dashboard**
  - Input data for future HBV treatment and prophylaxes coverage

**Historical trends**

- **Input**
  - Input data for all historical demographic and epidemiological variables of HBV

**Calculations**

- Calculations of disease progression from infection with HBV to death

**Outputs**

- Summary tables and figures of key output measures of prevalence and incidence
PRoGReSs — Economic Impact Module — Overview

**Historical trends**
- **Input**
  - Input data for all historical demographic and epidemiological variables of HBV

**Economic Impact Module**
- **EIM Inputs**
  - Inputs for diagnostic, healthcare, prophylaxes, and treatment costs, as well as economic losses associated with HBV infection
- **EIM Calculations**
  - Calculations for medical costs and economic losses associated with HBV infection to public and private health payers and patients
- **EIM Outputs**
  - Summary tables and figures displaying costs, cost-effectiveness, disease burden, and other outcomes of HBV strategy

**Future strategies**
- **Dashboard**
  - Input data for future HBV treatment and prophylaxes coverage
- **Calculations**
  - Calculations of disease progression from infection with HBV to death
Inputs — Medical costs

• **Medical costs**: monetary costs associated with managing chronic HBV infection and its sequelae
  » Prophylaxes
    - Vaccination \textit{per vaccination}
    - HBIG \textit{per dose}
    - Peripartum antiviral treatment of women \textit{per treatment}
  » Diagnostic
    - Screening (e.g., HBsAg test) \textit{per screen}
    - Laboratory (e.g., HBV DNA test) \textit{annual, per treated patient}
  » Healthcare
    - Inpatient
    - Outpatient
    - Medication, excluding antiviral treatment \textit{annual, per diagnosed patient}
  » Antiviral treatment \textit{annual, per treated patient}
Inputs — Medical costs

- **Medical costs**: monetary costs associated with managing chronic HBV infection and its sequelae
  - Prophylaxes costs are specified by
    - Scenario
    - Time (to reflect change in price)
  - Treatment and laboratory costs are specified by
    - Scenario (i.e., base case vs strategy)
    - Stage of liver disease
    - Time (to reflect change in price)
  - Healthcare costs are specified by
    - Stage of liver disease
  - All costs are further divided into
    - Costs paid by public or private health payers
    - Share paid by patient (copayment)
Inputs — Health effects and economic losses

- Health effects are denominated in disability-adjusted life years (DALYs)
  
  » DALY = Years of Life Lost (YLL) + Years Lost due to Disability (YLD)

  ▪ Years of Life Lost (YLL)
    - **Number of deaths** — HBV-related deaths calculated in PRoGReSs
    - **Life expectancy at age of death** — available from national census data or extrapolated based on estimates from UN World Population Prospects
    - **Discount rate** — depends on analysis

  ▪ Years Lost due to Disability (YLD)
    - **Number of incident cases** by stage of liver disease — calculated in PRoGReSs
    - **Disability weight** — published estimates
    - **Duration of disability** — calculated in PRoGReSs

---

**Inputs — Health effects and economic losses**

- Following parameters are used for calculating DALYs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disability weights</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decompensated cirrhosis</td>
<td>0.178</td>
<td>GBD 2016</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>0.466†</td>
<td></td>
</tr>
<tr>
<td>Liver transplant</td>
<td>0.024‡</td>
<td></td>
</tr>
<tr>
<td>Discount rate</td>
<td>3%</td>
<td>WHO 2003</td>
</tr>
<tr>
<td>Age-weighting modulation constant</td>
<td>0 (none)</td>
<td></td>
</tr>
</tbody>
</table>

† Weighted average of disability weights for terminal and controlled phases of liver cancer due to hepatitis C. It was assumed 85% of hepatocellular carcinoma cases were terminal (disability weight of 0.54) and 15% of cases were controlled (disability weight of 0.049).
‡ Disability weight for end-stage renal disease, with kidney transplant was used.
Inputs — Health effects and economic losses

• Economic losses associated with living with HBV infection are calculated in EIM

• Assume value of one DALY averted equals the GNI per capita* of country (Dalal 2013)

• Economic losses are calculated only for DALYs incurred at ages 20–69

---


* GNI per capita is used instead of GDP per capita because it reflects the average per-capita income in country
The WHO Targets scenario combines an aggressive prophylaxes strategy with screening and treatment requiring upfront investment.

- While screening costs do not decrease below base until 2028, savings in healthcare costs are seen almost immediately.
The combined scenario becomes cost-effective by 2020 and highly cost-effective by 2022.
Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- PRoGReSs Model
  - Overview
  - Model Validation
  - Economic Impact
  - Immigration
- Model
United States – In 2015, it was estimated that there were a maximum of 40,000 additional cases of chronic hepatitis B due to immigration

- The largest number of immigrants came from Mexico, and the largest number of chronic cases, 7,526, came from the Philippines

<table>
<thead>
<tr>
<th>Country of birth</th>
<th>Immigrants</th>
<th>Cases of HBV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mexico</td>
<td>158,619</td>
<td>210</td>
</tr>
<tr>
<td>China</td>
<td>74,558</td>
<td>5,940</td>
</tr>
<tr>
<td>India</td>
<td>64,116</td>
<td>1,820</td>
</tr>
<tr>
<td>Philippines</td>
<td>56,478</td>
<td>7,526</td>
</tr>
<tr>
<td>Cuba</td>
<td>54,396</td>
<td>323</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>50,610</td>
<td>1,258</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>30,832</td>
<td>3,405</td>
</tr>
<tr>
<td>Iraq</td>
<td>21,107</td>
<td>1,068</td>
</tr>
<tr>
<td>El Salvador</td>
<td>19,487</td>
<td>221</td>
</tr>
<tr>
<td>Pakistan</td>
<td>18,057</td>
<td>462</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,050,031</strong></td>
<td><strong>39,963</strong></td>
</tr>
</tbody>
</table>

These countries accounted for 52% of the total number of immigrants

United States- Total immigration and the country of origin have remained relatively constant from 2006-2015

### Table 3.
**Persons Obtaining Lawful Permanent Resident Status by Region and Country of Birth:**
**Fiscal Years 2006 to 2015**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REGION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,266,129</td>
<td>1,052,415</td>
<td>1,107,126</td>
<td>1,130,818</td>
<td>1,042,625</td>
<td>1,062,040</td>
<td>1,031,631</td>
<td>990,553</td>
<td>1,016,518</td>
<td>1,051,031</td>
</tr>
<tr>
<td>Africa</td>
<td>117,421</td>
<td>94,710</td>
<td>105,915</td>
<td>127,046</td>
<td>101,355</td>
<td>100,374</td>
<td>107,241</td>
<td>98,304</td>
<td>98,413</td>
<td>101,415</td>
</tr>
<tr>
<td>Asia</td>
<td>440,335</td>
<td>397,834</td>
<td>399,027</td>
<td>413,312</td>
<td>422,063</td>
<td>451,593</td>
<td>429,599</td>
<td>400,548</td>
<td>430,508</td>
<td>419,297</td>
</tr>
<tr>
<td>Europe</td>
<td>146,292</td>
<td>106,566</td>
<td>103,782</td>
<td>105,476</td>
<td>88,801</td>
<td>83,850</td>
<td>81,671</td>
<td>86,556</td>
<td>83,266</td>
<td>85,803</td>
</tr>
<tr>
<td>North America</td>
<td>413,992</td>
<td>339,294</td>
<td>393,196</td>
<td>375,180</td>
<td>336,553</td>
<td>333,902</td>
<td>327,771</td>
<td>315,660</td>
<td>324,354</td>
<td>366,126</td>
</tr>
<tr>
<td>Oceania</td>
<td>7,384</td>
<td>6,101</td>
<td>5,263</td>
<td>5,578</td>
<td>5,345</td>
<td>4,980</td>
<td>4,742</td>
<td>5,277</td>
<td>5,112</td>
<td>5,404</td>
</tr>
<tr>
<td>South America</td>
<td>137,971</td>
<td>106,516</td>
<td>98,549</td>
<td>102,860</td>
<td>87,178</td>
<td>86,096</td>
<td>79,401</td>
<td>80,945</td>
<td>73,715</td>
<td>72,309</td>
</tr>
<tr>
<td>Unknown</td>
<td>2,734</td>
<td>1,394</td>
<td>1,394</td>
<td>1,366</td>
<td>1,330</td>
<td>1,245</td>
<td>1,206</td>
<td>3,263</td>
<td>1,150</td>
<td>677</td>
</tr>
<tr>
<td><strong>Mexico</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>173,749</td>
<td>148,640</td>
<td>189,989</td>
<td>164,920</td>
<td>139,120</td>
<td>143,446</td>
<td>146,406</td>
<td>135,028</td>
<td>134,052</td>
<td>158,619</td>
</tr>
<tr>
<td><strong>China, People’s Republic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China, People’s Republic</td>
<td>87,307</td>
<td>76,655</td>
<td>80,271</td>
<td>64,238</td>
<td>70,863</td>
<td>87,016</td>
<td>81,784</td>
<td>71,798</td>
<td>76,089</td>
<td>74,558</td>
</tr>
<tr>
<td><strong>India</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>India</td>
<td>61,369</td>
<td>65,353</td>
<td>63,352</td>
<td>57,304</td>
<td>69,162</td>
<td>69,013</td>
<td>66,434</td>
<td>68,458</td>
<td>77,908</td>
<td>64,116</td>
</tr>
<tr>
<td><strong>Philippines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philippines</td>
<td>74,606</td>
<td>72,596</td>
<td>54,030</td>
<td>60,029</td>
<td>58,173</td>
<td>57,011</td>
<td>57,327</td>
<td>54,446</td>
<td>49,996</td>
<td>56,478</td>
</tr>
<tr>
<td><strong>Cuba</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cuba</td>
<td>45,614</td>
<td>29,104</td>
<td>49,500</td>
<td>38,954</td>
<td>33,573</td>
<td>36,452</td>
<td>32,820</td>
<td>32,219</td>
<td>46,679</td>
<td>54,396</td>
</tr>
<tr>
<td><strong>Dominican Republic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>38,068</td>
<td>28,024</td>
<td>31,879</td>
<td>49,414</td>
<td>53,870</td>
<td>46,109</td>
<td>41,566</td>
<td>41,311</td>
<td>44,577</td>
<td>50,610</td>
</tr>
<tr>
<td><strong>Vietnam</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Iraq</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iraq</td>
<td>4,337</td>
<td>3,765</td>
<td>4,795</td>
<td>12,110</td>
<td>19,855</td>
<td>21,133</td>
<td>20,369</td>
<td>9,552</td>
<td>19,153</td>
<td>21,107</td>
</tr>
<tr>
<td><strong>El Salvador</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>El Salvador</td>
<td>31,782</td>
<td>21,127</td>
<td>19,659</td>
<td>19,909</td>
<td>18,806</td>
<td>18,667</td>
<td>16,256</td>
<td>18,260</td>
<td>19,273</td>
<td>19,487</td>
</tr>
<tr>
<td><strong>Pakistan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pakistan</td>
<td>17,418</td>
<td>13,492</td>
<td>19,719</td>
<td>21,555</td>
<td>18,258</td>
<td>15,546</td>
<td>14,740</td>
<td>13,251</td>
<td>18,612</td>
<td>18,057</td>
</tr>
</tbody>
</table>
Outputs – Prevalence is expected to stabilize and then begin decreasing when including immigration

• In 2016, it is estimated that there were 885,000 chronic hepatitis B infections in the United States. By 2027, the total infected population is expected to stabilize at approximately 955,000 before beginning to decrease in 2030 to 926,000 in 2036
Outputs - Incidence of chronic hepatitis B is expected to decrease through 2036 as the impact of vaccination is observed globally

- In 2016, the incidence of chronic hepatitis B was estimated to be 42,000 dropping to 25,000 by 2036
  - 95% of new chronic cases were due to immigration in 2016, but this increased to 99% by 2032
Topics

- CDAF Background
- Delphi Process
- Global Work
- State Work
- PRoGReSs Model
  » Overview
  » Model Validation
  » Economic Impact
  » Immigration
- Model
References


• Cui F, Shen L, Li L, et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Disease journal 2017; 23(5): 765–72


• Polaris Observatory (http://cdafound.org/polaris/) accessed June 14, 2018


References continued

• Soipe AI, Razavi H, Razavi-Shearer D, Galarraga O, Taylor LE, Marshall BD. Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination. Epidemiol Infect. 2016;11

• United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Prospects: the 2017 Revision


Q & A

Please submit questions in the chat box!
Thank you for joining!

Contact us:
connect@hepbunited.org
www.hepbunited.org